LAMA84-r SMAD/TGFbeta Reporter (Luc) stable cell line

LAMA84-r SMAD/TGFbeta Reporter (Luc) cells are derived from the human chronic myeloid leukemia cell line LAMA84-r by stably integration of a SMAD/TGFbeta firefly luciferase reporter construct. The LAMA84-r cell line is resistant to the tyrosine kinase inhibitor imatinib mesylate, and is paired to the LAMA84-s cell line which is sensitive to imatinib. The paired LAMA84-r and LAMA84-s cell lines are useful models of sensitivity and resistance to a tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia. LAMA84-r SMAD/TGFbeta Reporter (Luc) cells stably express firefly luciferase under the control of the SMAD/TGFbeta response elements, can be used for monitoring the activity of TGF?/SMAD signaling pathway.